Concepts (167)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carotid Artery Diseases | 7 | 2020 | 91 | 2.260 |
Why?
|
| Dyslipidemias | 4 | 2017 | 106 | 1.900 |
Why?
|
| Hypolipidemic Agents | 6 | 2018 | 101 | 1.720 |
Why?
|
| Lipids | 4 | 2014 | 281 | 1.690 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 4 | 2020 | 360 | 1.530 |
Why?
|
| Atherosclerosis | 5 | 2016 | 223 | 1.210 |
Why?
|
| Coronary Artery Disease | 4 | 2021 | 328 | 1.150 |
Why?
|
| Carotid Arteries | 4 | 2018 | 126 | 1.130 |
Why?
|
| Carotid Intima-Media Thickness | 3 | 2020 | 38 | 0.880 |
Why?
|
| HIV Infections | 2 | 2020 | 669 | 0.820 |
Why?
|
| Plaque, Atherosclerotic | 3 | 2018 | 40 | 0.790 |
Why?
|
| Cause of Death | 1 | 2020 | 273 | 0.720 |
Why?
|
| Heart Sounds | 1 | 2017 | 1 | 0.660 |
Why?
|
| American Heart Association | 1 | 2017 | 83 | 0.630 |
Why?
|
| Primary Prevention | 1 | 2017 | 83 | 0.610 |
Why?
|
| Cyclin D1 | 1 | 2016 | 81 | 0.590 |
Why?
|
| Myocardial Contraction | 1 | 2017 | 242 | 0.590 |
Why?
|
| Pericardium | 1 | 2016 | 68 | 0.570 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2016 | 157 | 0.570 |
Why?
|
| Guideline Adherence | 1 | 2017 | 215 | 0.560 |
Why?
|
| Foramen Ovale, Patent | 1 | 2015 | 15 | 0.560 |
Why?
|
| Anticholesteremic Agents | 2 | 2016 | 137 | 0.550 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2016 | 116 | 0.510 |
Why?
|
| Carotid Stenosis | 2 | 2012 | 103 | 0.510 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2016 | 1168 | 0.500 |
Why?
|
| Thrombosis | 2 | 2015 | 268 | 0.500 |
Why?
|
| Adipose Tissue | 1 | 2016 | 238 | 0.500 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2012 | 3121 | 0.500 |
Why?
|
| Azetidines | 2 | 2016 | 37 | 0.490 |
Why?
|
| Cardiovascular Diseases | 3 | 2015 | 793 | 0.480 |
Why?
|
| Coronary Stenosis | 1 | 2012 | 39 | 0.460 |
Why?
|
| Heart Diseases | 1 | 2015 | 290 | 0.460 |
Why?
|
| Jejunum | 1 | 2012 | 75 | 0.450 |
Why?
|
| Intestinal Absorption | 1 | 2012 | 122 | 0.450 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2017 | 558 | 0.440 |
Why?
|
| Heart Ventricles | 1 | 2017 | 733 | 0.430 |
Why?
|
| MicroRNAs | 1 | 2016 | 512 | 0.420 |
Why?
|
| Cholesterol, HDL | 4 | 2017 | 165 | 0.410 |
Why?
|
| Disease Progression | 4 | 2020 | 1450 | 0.400 |
Why?
|
| Practice Guidelines as Topic | 1 | 2017 | 1036 | 0.380 |
Why?
|
| Cholesterol, LDL | 6 | 2018 | 215 | 0.360 |
Why?
|
| Blood Glucose | 1 | 2012 | 857 | 0.340 |
Why?
|
| Hypertension | 1 | 2017 | 1210 | 0.340 |
Why?
|
| Middle Aged | 14 | 2020 | 24186 | 0.340 |
Why?
|
| Chagas Cardiomyopathy | 1 | 2006 | 4 | 0.310 |
Why?
|
| Trypanosoma cruzi | 1 | 2006 | 8 | 0.310 |
Why?
|
| Humans | 24 | 2021 | 81624 | 0.310 |
Why?
|
| Lipoproteins, HDL | 1 | 2006 | 96 | 0.300 |
Why?
|
| Male | 15 | 2020 | 39845 | 0.260 |
Why?
|
| Niacin | 4 | 2016 | 37 | 0.250 |
Why?
|
| Risk Factors | 4 | 2020 | 5185 | 0.250 |
Why?
|
| Treatment Outcome | 6 | 2018 | 7608 | 0.250 |
Why?
|
| Magnetic Resonance Angiography | 2 | 2018 | 249 | 0.230 |
Why?
|
| Chi-Square Distribution | 2 | 2017 | 358 | 0.220 |
Why?
|
| Biomarkers | 4 | 2018 | 1611 | 0.220 |
Why?
|
| Follow-Up Studies | 4 | 2020 | 3592 | 0.210 |
Why?
|
| Heart Transplantation | 1 | 2006 | 656 | 0.210 |
Why?
|
| Incidence | 3 | 2015 | 1553 | 0.200 |
Why?
|
| Cell Proliferation | 2 | 2016 | 1545 | 0.190 |
Why?
|
| Time Factors | 4 | 2018 | 5175 | 0.190 |
Why?
|
| Coronary Angiography | 2 | 2012 | 205 | 0.180 |
Why?
|
| Female | 11 | 2020 | 42784 | 0.180 |
Why?
|
| Lipoprotein(a) | 1 | 2018 | 28 | 0.170 |
Why?
|
| Proportional Hazards Models | 2 | 2017 | 831 | 0.170 |
Why?
|
| Compliance | 1 | 2017 | 24 | 0.160 |
Why?
|
| Heart Failure | 1 | 2006 | 1101 | 0.160 |
Why?
|
| Asymptomatic Diseases | 1 | 2017 | 38 | 0.160 |
Why?
|
| Chest Pain | 1 | 2017 | 36 | 0.160 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2016 | 869 | 0.160 |
Why?
|
| Microphthalmia-Associated Transcription Factor | 1 | 2016 | 14 | 0.150 |
Why?
|
| Antigens, Nuclear | 1 | 2016 | 25 | 0.150 |
Why?
|
| Melanocytes | 1 | 2016 | 55 | 0.150 |
Why?
|
| Linear Models | 1 | 2017 | 404 | 0.150 |
Why?
|
| 3' Untranslated Regions | 1 | 2016 | 90 | 0.150 |
Why?
|
| Proprotein Convertases | 1 | 2015 | 24 | 0.150 |
Why?
|
| Immunoblotting | 1 | 2016 | 266 | 0.140 |
Why?
|
| Adult | 8 | 2018 | 24854 | 0.140 |
Why?
|
| Antiphospholipid Syndrome | 1 | 2015 | 17 | 0.140 |
Why?
|
| Electronic Nicotine Delivery Systems | 1 | 2015 | 48 | 0.130 |
Why?
|
| Multivariate Analysis | 1 | 2017 | 968 | 0.130 |
Why?
|
| Clinical Trials as Topic | 3 | 2016 | 1154 | 0.130 |
Why?
|
| Cell Cycle | 1 | 2016 | 500 | 0.130 |
Why?
|
| Longitudinal Studies | 1 | 2017 | 954 | 0.130 |
Why?
|
| Heptanoic Acids | 2 | 2011 | 73 | 0.130 |
Why?
|
| Cisplatin | 1 | 2016 | 593 | 0.130 |
Why?
|
| Cohort Studies | 1 | 2020 | 2603 | 0.120 |
Why?
|
| Molecular Targeted Therapy | 1 | 2015 | 259 | 0.120 |
Why?
|
| Nerve Tissue Proteins | 1 | 2016 | 496 | 0.120 |
Why?
|
| Pyrroles | 2 | 2011 | 184 | 0.120 |
Why?
|
| Ezetimibe | 1 | 2012 | 31 | 0.120 |
Why?
|
| Apoptosis | 2 | 2016 | 1655 | 0.110 |
Why?
|
| Risk Assessment | 1 | 2020 | 2182 | 0.110 |
Why?
|
| Melanoma | 1 | 2016 | 432 | 0.110 |
Why?
|
| Simvastatin | 2 | 2016 | 106 | 0.110 |
Why?
|
| Drug Therapy, Combination | 1 | 2014 | 907 | 0.110 |
Why?
|
| Global Health | 1 | 2013 | 190 | 0.110 |
Why?
|
| Smoking | 1 | 2015 | 600 | 0.100 |
Why?
|
| Cell Line | 1 | 2016 | 2474 | 0.100 |
Why?
|
| Cell Line, Tumor | 1 | 2016 | 2334 | 0.100 |
Why?
|
| Case-Control Studies | 1 | 2014 | 1746 | 0.090 |
Why?
|
| Age Factors | 1 | 2014 | 1805 | 0.090 |
Why?
|
| Transcription Factors | 1 | 2016 | 1488 | 0.090 |
Why?
|
| Aged | 3 | 2018 | 17608 | 0.070 |
Why?
|
| Carotid Artery, Common | 1 | 2006 | 28 | 0.070 |
Why?
|
| Carotid Artery, Internal | 1 | 2006 | 65 | 0.070 |
Why?
|
| United States | 1 | 2017 | 6212 | 0.070 |
Why?
|
| Gadolinium DTPA | 1 | 2006 | 255 | 0.070 |
Why?
|
| Antineoplastic Agents | 1 | 2016 | 2288 | 0.070 |
Why?
|
| Magnetic Resonance Imaging, Cine | 1 | 2006 | 151 | 0.070 |
Why?
|
| Double-Blind Method | 3 | 2018 | 1812 | 0.060 |
Why?
|
| Animals | 3 | 2015 | 25907 | 0.060 |
Why?
|
| Contrast Media | 1 | 2006 | 1017 | 0.050 |
Why?
|
| Predictive Value of Tests | 2 | 2018 | 1625 | 0.050 |
Why?
|
| Lipid Metabolism | 2 | 2011 | 193 | 0.040 |
Why?
|
| Colestipol | 1 | 2016 | 3 | 0.040 |
Why?
|
| Lovastatin | 1 | 2016 | 28 | 0.040 |
Why?
|
| Luciferases | 1 | 2016 | 119 | 0.040 |
Why?
|
| Hyperlipoproteinemias | 1 | 2015 | 7 | 0.040 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2016 | 130 | 0.040 |
Why?
|
| Proprotein Convertase 9 | 1 | 2015 | 17 | 0.040 |
Why?
|
| Oligonucleotides, Antisense | 1 | 2015 | 69 | 0.040 |
Why?
|
| Triglycerides | 1 | 2016 | 231 | 0.040 |
Why?
|
| Receptors, LDL | 1 | 2015 | 52 | 0.040 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2016 | 318 | 0.040 |
Why?
|
| Streptokinase | 1 | 1995 | 12 | 0.030 |
Why?
|
| Pulmonary Valve Insufficiency | 1 | 1995 | 11 | 0.030 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2016 | 266 | 0.030 |
Why?
|
| Transcriptional Activation | 1 | 2016 | 277 | 0.030 |
Why?
|
| Serine Endopeptidases | 1 | 2015 | 146 | 0.030 |
Why?
|
| Structure-Activity Relationship | 1 | 2015 | 401 | 0.030 |
Why?
|
| Heart Valve Prosthesis | 1 | 1995 | 88 | 0.030 |
Why?
|
| Adipocytes | 1 | 2015 | 142 | 0.030 |
Why?
|
| Blotting, Western | 1 | 2016 | 778 | 0.030 |
Why?
|
| RNA Interference | 1 | 2015 | 357 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2016 | 849 | 0.030 |
Why?
|
| RNA, Small Interfering | 1 | 2015 | 539 | 0.030 |
Why?
|
| Peptide Fragments | 1 | 2015 | 458 | 0.030 |
Why?
|
| Protein Structure, Tertiary | 1 | 2015 | 744 | 0.030 |
Why?
|
| Binding Sites | 1 | 2016 | 1084 | 0.030 |
Why?
|
| Smoking Cessation | 1 | 2015 | 220 | 0.030 |
Why?
|
| Promoter Regions, Genetic | 1 | 2016 | 918 | 0.030 |
Why?
|
| Thrombolytic Therapy | 1 | 1995 | 186 | 0.030 |
Why?
|
| Idaho | 1 | 2011 | 7 | 0.030 |
Why?
|
| Apolipoproteins B | 1 | 2011 | 39 | 0.030 |
Why?
|
| Washington | 1 | 2011 | 47 | 0.030 |
Why?
|
| Epigenesis, Genetic | 1 | 2015 | 437 | 0.030 |
Why?
|
| Necrosis | 1 | 2011 | 192 | 0.030 |
Why?
|
| Prospective Studies | 2 | 2011 | 3978 | 0.030 |
Why?
|
| Cells, Cultured | 1 | 2016 | 2798 | 0.030 |
Why?
|
| Fibrosis | 1 | 2011 | 193 | 0.020 |
Why?
|
| Liver | 1 | 2015 | 1203 | 0.020 |
Why?
|
| Intestinal Mucosa | 1 | 2015 | 801 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2016 | 1942 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2015 | 902 | 0.020 |
Why?
|
| Antibodies, Monoclonal | 1 | 2015 | 1378 | 0.020 |
Why?
|
| Colesevelam Hydrochloride | 1 | 2007 | 11 | 0.020 |
Why?
|
| Allylamine | 1 | 2007 | 11 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2018 | 6246 | 0.020 |
Why?
|
| Calcium | 1 | 2011 | 1135 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2015 | 2195 | 0.020 |
Why?
|
| Brain | 1 | 2015 | 2059 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2016 | 3168 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 1995 | 2104 | 0.020 |
Why?
|
| Mutation | 1 | 2015 | 3819 | 0.020 |
Why?
|
| Mice | 1 | 2015 | 10886 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2006 | 2602 | 0.010 |
Why?
|
| Prosthesis Design | 1 | 1995 | 270 | 0.010 |
Why?
|